基于DM2的体系结构可执行模型构建方法

基于元模型的体系结构设计思想和基于可执行模型的评估方法是体系结构领域研究的两个热点,但当前的研究没有将两者结合起来。文章基于DoDAF2.0提出的元模型数据(Meta-Model Data,DM2),将元模型的思想和基于可执行模型的评估方法相结合,分析了基于DM2的逻辑数据与可执行模型各构建要素的对应关系,构建了基于DM2的逻辑数据模型直接转可执行模型的过程框架,重点研究了如何直接从体系结构底层数据转可执行模型的方法,从而为进行基于元模型的体系结构可执行评估提供模型基础,也为进一步实现体系结构自动化验证评估提供技术支持。实例验证了文章提出的方法。

基于DM2的体系结构数据完备性验证方法

为进行有效、规范的体系结构构建,现有体系结构大多采用美国国防部体系结构框架(Department of Defense architecture framework,DoDAF)作为指导,针对采用该框架构建的体系结构的数据完备性验证问题,提出了一种基于国防部体系结构框架元模型(DoDAF meta-model,DM2)的验证方法。该方法利用DM2中数据实体之间的关系,直接从DM2中提取数据的完备性规则,进而构建完备性验证矩阵,并通过验证矩阵判断体系结构数据的完备性。最后,通过一个案例进行完备性验证步骤说明和可行性分析,验证结果说明了该方法的有效性。

Insulin Glargine 300 Units/mL Effectiveness in Patients with T2DM Uncontrolled by Basal Insulin in Real-Life Settings in the Czech Republic

Introduction: To evaluate the clinical effectiveness of Gla-300 units/mL (Gla-300) in the treatment of patients with type 2 diabetes (T2DM) uncontrolled by basal insulin in real-life clinical settings in the Czech Republic (TOPAZ study). Methods: TOPAZ was a prospective, multi-center, non-interventional, 6-month study. Of the 312 patients screened, 289 were evaluated at month 6. The primary objective was the change of HbA1c after 6 months. The proportion of patients with HbA1c < 7.0% DCCT (< 53 mmol/mol), and those with a decrease of at least 0.5% of HbA1c at month 6, change in FPG, body weight and insulin dose at month 3 and 6 were analysed as secondary objectives. Incidence of hypoglycemia, adverse events and patient treatment satisfaction were also assessed. Results: HbA1c decreased significantly after 6 months (mean change 0.9% ± 1.1% DCCT [−9.9 ± 11.6 mmol/mol], p < 0.0001). HbA1c target < 7.0% DCCT was achieved in 17.6% of patients, 66.1% of patients showed mean HbA1c decrease of 0.5% ± 0.8%. At month 6, FPG decreased (mean change from baseline −1.8 ± 3.1 mmol/L) as well as the incidence of hypoglycemia decreased by 49% (p < 0.0001) while no weight gain was observed. No significant safety signals were identified. Conclusion: In a real-life setting, switching to Gla-300 in T2DM patients uncontrolled with other basal insulin was associated with improved glycemic control and reduced risk of hypoglycemia without weight gain, while patients’ satisfaction with treatment increased.